E-mail: bd@sidmexinovia.com
Telefone: +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Biomab 50 mg Injection
Manufacturer/Marketed By : Biocon Biologics India Ltd
$815.96 $679.97
Biomab 50 mg Injection is a humanized monoclonal antibody specifically designed to target the epidermal growth factor receptor (EGFR), a crucial player in the growth of certain cancers. This innovative...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
Nimotuzumab 50 mg
Active Pharmaceutical Ingredient
Biomab 50 mg Injection
US$ 815,96
US$ 679,97
Biomab 50 mg Injection is a humanized monoclonal antibody specifically designed to target the epidermal growth factor receptor (EGFR), a crucial player in the growth of certain cancers. This innovative treatment option is utilized both as a standalone therapy and in combination with chemotherapy and radiotherapy, making it effective for patients suffering from various malignancies, including head and neck cancers, colorectal cancer, and specific types of brain tumors such as glioma and glioblastoma. By inhibiting the signals that promote cancer cell proliferation, Biomab helps to slow down tumor growth and improve patient outcomes. It's essential to monitor for potential side effects, which may include allergic reactions and infusion-related symptoms, so healthcare providers can manage any adverse reactions effectively. Patients are advised to discuss their medical history and current medications with their healthcare team to ensure safe use. Biomab 50 mg is an integral part of modern oncological care, offering hope for improved survival rates in challenging cancer types. With its targeted mechanism of action, this injection represents a significant advancement in cancer treatment strategies.
Active Pharmaceutical Ingredient
Usos
• Biomab 50 mg injection is utilized in the treatment of head and neck cancer. This medication targets specific cancer cells, helping to inhibit their growth and spread. Patients with this type of cancer may benefit from Biomab 50 mg injection as part of a comprehensive treatment plan. It is typically administered in conjunction with other therapies to enhance overall efficacy.
• In cases of colorectal cancer, Biomab 50 mg injection plays a significant role in managing the disease. This injection works by blocking pathways that cancer cells use to proliferate. By including Biomab 50 mg injection in the treatment regimen, oncologists aim to improve patient outcomes. It can be an essential component of therapy for individuals facing this challenging diagnosis.
• Biomab 50 mg injection is also indicated for glioblastoma, a type of aggressive brain cancer. The medication helps to target and attack tumor cells, which can lead to better control of the disease. For patients diagnosed with glioblastoma, Biomab 50 mg injection may be used alongside other treatment modalities. This approach is designed to maximize therapeutic effects and improve quality of life.
Benefícios
Head and neck cancer: Head and neck cancer includes cancers of the mouth, nose, sinuses or throat. Nimotuzumab Injection 50 mg kills or stops the growth of cancer cells and also prevents cancer cells from multiplying. It is a strong and very toxic medicine, and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol or smoking during this treatment and drink plenty of water to stay hydrated. Cancer of the colon and rectum: Cancer of the colon and rectum, also known as colorectal cancer (CRC) or bowel cancer, is the development of cancer in two parts of the large intestine, the colon or rectum. With this type of cancer, a person may notice symptoms such as blood in the stool, a change in bowel movements, weight loss and fatigue. Biomab Injection treats and also reduces the risk of developing other cancerous growths (polyps) and bowel cancer. It kills or stops the growth of cancer cells and also stops cancer cells from multiplying. It is an effective medicine, but it does have some side effects. Talk to your physician when you have any concerns. Glioblastoma (cancer of the brain and spinal cord) Glioblastoma is a type of cancer that starts as a growth of cells in the brain or spinal cord. It works by targeting the epidermal growth factor receptor (EGFR), which is often found in high levels on the surface of glioblastoma cells. By binding to EGFR, Biomab 50 mg can interfere with the growth and spread of these cancer cells.
Efeitos colaterais
Like all medicines, Biomab 50 mg Injection may cause side effects which do not require medical attention and which will disappear as your body adjusts to the medicine. Tell your doctor if they persist or if you're worried about them.
Efeitos colaterais mais comuns
• Fever
• Rashes
• Itching
• Nausea
• Vomiting
• Chills
• Rigors
• Altered liver enzymes
Efeitos colaterais comuns
• Drowsiness
• Disorientation
• Changes in blood pressure like hypotension or hypertension
• Hematuria ( Blood in urine)
• Weakness
• Allergic reaction
• Fatigue
• Diarrhoea
• Dizziness
Como usar
Biomab 50 mg Vial is used as an IV (intravenous) infusion to be given intravenously into a vein under the supervision of a healthcare professional. This medicine must be given slowly as advised by your doctor. Don't give yourself medicine at home without medical supervision.
Conselhos de segurança
• Alcohol: Drinking alcohol while taking Biomab 50 mg is generally not recommended. It may increase the risk of liver damage and it is best to avoid alcohol or to limit the amount of alcohol you drink while you are taking this medicine.
• Kidney: In patients with kidney disease, Biomab 50 mg Injection should be used with caution and kidney function should be closely monitored. If you experience any side effects or you have concerns about using this Biomab Injection, please consult your doctor.
• Breastfeeding: There are no data on the presence of Biomab 50 mg or its metabolites in human milk or effects on nursing infants or lactation. Because of the potential for serious adverse reactions in nursing infants, women should be advised not to breastfeed during treatment with Biomab Injection and for 2 weeks after the last dose.
• Liver: In patients with liver disease, Nimotuzumab Injection 50 mg should be used with caution, and liver function should be closely monitored. If you experience any side effects or have concerns about using this Biomab Injection, please consult your doctor.
• Pregnancy: The use of Anti-cancer Drug Biomab is not recommended in pregnant women as it may cause harm to the foetus if administered to a pregnant woman.
• Driving: Biomab 50 mg Injection may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Biomab 50 mg.
Isenção de responsabilidade
A Sidmex Inovia se esforça para fornecer informações precisas e confiáveis; no entanto, todo o conteúdo deste site, incluindo descrições e composições de produtos, tem caráter meramente informativo e não deve ser considerado um substituto para aconselhamento, diagnóstico ou tratamento médico profissional.
Recomenda-se aos usuários que consultem um profissional de saúde qualificado antes de tomar qualquer decisão médica. As informações fornecidas não devem ser usadas para autodiagnóstico ou automedicação.
Todos os produtos listados destinam-se estritamente a consultas B2B e em grandes quantidades. A Sidmex Inovia não promove o uso direto pelo consumidor e visa apoiar, e não substituir, a relação entre o profissional de saúde e o paciente.
Os nomes de produtos, marcas comerciais e marcas pertencem aos seus respectivos proprietários, e seu uso não implica qualquer afiliação ou endosso. A Sidmex Inovia não se responsabiliza por quaisquer consequências decorrentes do uso das informações fornecidas neste site.